Equities research analysts expect that Puma Biotechnology Inc (NASDAQ:PBYI) will post $69.32 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Puma Biotechnology’s earnings, with the highest sales estimate coming in at $74.00 million and the lowest estimate coming in at $64.63 million. The company is expected to announce its next earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Puma Biotechnology will report full year sales of $235.37 million for the current financial year, with estimates ranging from $235.00 million to $235.73 million. For the next year, analysts expect that the business will report sales of $474.61 million per share, with estimates ranging from $427.11 million to $522.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, topping the consensus estimate of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to the consensus estimate of $20.83 million. During the same period in the prior year, the business earned ($1.22) earnings per share.
In other Puma Biotechnology news, SVP Richard Paul Bryce sold 1,860 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the sale, the senior vice president now owns 25,379 shares of the company’s stock, valued at approximately $2,353,902.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alan H. Auerbach sold 10,692 shares of the firm’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $92.75, for a total value of $991,683.00. Following the sale, the insider now directly owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. Company insiders own 21.10% of the company’s stock.
A number of institutional investors have recently made changes to their positions in PBYI. BlackRock Inc. lifted its holdings in Puma Biotechnology by 31.4% during the 4th quarter. BlackRock Inc. now owns 2,385,036 shares of the biopharmaceutical company’s stock valued at $235,763,000 after purchasing an additional 570,393 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Puma Biotechnology by 796.5% during the 4th quarter. Wells Fargo & Company MN now owns 524,933 shares of the biopharmaceutical company’s stock valued at $51,890,000 after purchasing an additional 466,382 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Puma Biotechnology by 265.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock valued at $57,743,000 after purchasing an additional 350,300 shares during the last quarter. Eagle Asset Management Inc. acquired a new stake in Puma Biotechnology during the 4th quarter valued at $28,918,000. Finally, Carillon Tower Advisers Inc. acquired a new stake in Puma Biotechnology during the 4th quarter valued at $20,543,000. 95.95% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:PBYI traded up $0.70 during midday trading on Tuesday, hitting $66.80. The stock had a trading volume of 668,591 shares, compared to its average volume of 947,215. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90. The company has a current ratio of 1.82, a quick ratio of 1.79 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $2,504.59, a PE ratio of -8.51 and a beta of 0.15.
ILLEGAL ACTIVITY NOTICE: “$69.32 Million in Sales Expected for Puma Biotechnology Inc (PBYI) This Quarter” was reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://weekherald.com/2018/04/18/69-32-million-in-sales-expected-for-puma-biotechnology-inc-pbyi-this-quarter.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.